Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
973.8 ^USD	+0.60%		+1.76%	+10.87%

May. 08	Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	CI
May. 07	UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating	MT

Regeneron Pharmaceuticals, Inc. Appoints Philip Gregory as Senior Vice President and Head of Regeneron Cell Medicines

January 29, 2024

Regeneron Pharmaceuticals, Inc. (REGN) announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, to acquire full development and commercialization rights to its pipeline of investigational immune cell therapies. Philip Gregory, currently the Chief Scientific Officer of 2seventy bio, will be appointed Senior Vice President and Head of Regeneron Cell Medicines.

Latest news about Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	May. 08	CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating	May. 07	MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept	May. 03	MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126	May. 03	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177	May. 02	MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016	May. 02	MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189	May. 02	MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday	May. 02	MT
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Regeneron: Adjusted EPS down 4% in Q1	May. 02	CF
Fed, Earnings Outlooks Lift Wall Street Pre-Bell; Asia Mixed, Europe Off	May. 02	MT
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 3, 2023.	May. 02	CI
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales	May. 02	DJ
Regeneron Pharmaceuticals' Q1 Non-GAAP Net Income, Revenue Decline	May. 02	MT
Regeneron Pharmaceuticals, Inc. announces an Equity Buyback for $3,000 million worth of its shares.	May. 02	CI
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn	May. 02	MT
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 Revenue $3.15B, vs. Street Est of $3.22B	May. 02	MT
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 EPS $9.55, vs. Street Est of $10.10	May. 02	MT
Regeneron misses profit estimates on weaker Eylea and Dupixent sales	May. 02	RE
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says	Apr. 26	MT
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	Apr. 26	MT
Regeneron Pharmaceuticals Receives a Shareholder Proposal from John Chevedden	Apr. 25	CI
Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences	Apr. 25	DJ

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Sector

Biotechnology & Medical Research

Calendar

08:00am - American Society of Gene & Cell Therapy Meeting - Pressing Challenges in Gene Therapy

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

973.8 USD

Average target price

1,028 USD

Spread / Average Target

+5.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B
VIKING THERAPEUTICS, INC.	+295.70%	8.12B

Bio Therapeutic Drugs